share_log

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Feb 2 05:03
Summary by Futu AI
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced on February 1, 2024, an exclusive long-term licensing agreement with BIRAD, the research and development arm of Bar-Ilan University in Israel. This agreement grants Clearmind the rights to use a joint patent with BIRAD for an innovative treatment for cocaine addiction. The treatment is based on the compound MEAI [5-Methoxy-2-aminoindane], which has shown promising results in pre-clinical trials by significantly reducing cocaine craving and addiction. The trials, led by Professor Gal Yadid at the Gonda Multidisciplinary Brain Research Center, utilized the self-administration paradigm to demonstrate MEAI's potential in treating cocaine addiction without being addictive itself. Clearmind's CEO, Dr. Adi Zuloff-Shani, expressed that securing the exclusive rights aligns with the company's strategic decision to ensure maximum returns for shareholders and to provide innovative treatments for addiction. The company's shares are traded on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange under the symbols 'CMND' and 'CWY' respectively.
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced on February 1, 2024, an exclusive long-term licensing agreement with BIRAD, the research and development arm of Bar-Ilan University in Israel. This agreement grants Clearmind the rights to use a joint patent with BIRAD for an innovative treatment for cocaine addiction. The treatment is based on the compound MEAI [5-Methoxy-2-aminoindane], which has shown promising results in pre-clinical trials by significantly reducing cocaine craving and addiction. The trials, led by Professor Gal Yadid at the Gonda Multidisciplinary Brain Research Center, utilized the self-administration paradigm to demonstrate MEAI's potential in treating cocaine addiction without being addictive itself. Clearmind's CEO, Dr. Adi Zuloff-Shani, expressed that securing the exclusive rights aligns with the company's strategic decision to ensure maximum returns for shareholders and to provide innovative treatments for addiction. The company's shares are traded on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange under the symbols 'CMND' and 'CWY' respectively.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.